Johnson & Johnson’s trials show 85% efficacy against severe Covid disease. Company will apply for FDA emergency authorization next week.

The vaccine was 72% effective against moderate and severe disease in the US, the company said. It’s a striking difference from vaccines from Pfizer/BioNTech and Moderna, and it may give … Read More

Loading

Follow by Email
Pinterest
LinkedIn
Share